BR112018008011A2 - proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv - Google Patents

proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv

Info

Publication number
BR112018008011A2
BR112018008011A2 BR112018008011A BR112018008011A BR112018008011A2 BR 112018008011 A2 BR112018008011 A2 BR 112018008011A2 BR 112018008011 A BR112018008011 A BR 112018008011A BR 112018008011 A BR112018008011 A BR 112018008011A BR 112018008011 A2 BR112018008011 A2 BR 112018008011A2
Authority
BR
Brazil
Prior art keywords
binding proteins
prevention
treatment
trypecific
hiv infection
Prior art date
Application number
BR112018008011A
Other languages
English (en)
Inventor
Yang Zhi-Yong
Beil Christian
Lange Christian
Connors Mark
R. Mascola John
A. Koup Richard
Huang Jinghe
A. Doria-Rose Nicole
Zhou Tongqing
D. Kwong Peter
Do Kwon Young
J. Nabel Gary
Pegu Amarendra
Xu Ling
Wei Ronnie
Qiu Huawei
Beninga Jochen
Kruip Jochen
Rao Ercole
Dirk Leuschner Wulf
Asokan Mangaiarkarasi
Original Assignee
Sanofi
The Usa, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, The Usa, As Represented By The Secretary, Department Of Health And Human Services filed Critical Sanofi
Publication of BR112018008011A2 publication Critical patent/BR112018008011A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção refere-se a composições compreendendo proteínas de ligação triespecíficas e/ou trivalentes compreendendo quatro cadeias de polipeptídeo que formam três sítios de ligação de antígeno que se ligam especificamente a uma ou mais proteínas-alvo do hiv ou um ou mais receptores de célula t, onde o primeiro par de polipeptídeos formando a proteína de ligação possui domínios variáveis duplos tendo uma orientação cruzada e onde o segundo par de polipeptídeos formando a proteína de ligação possui um domínio variável único. são também providos aqui métodos para produção de proteínas de ligação triespecíficas e/ou trivalentes e usos de tais proteínas de ligação para o tratamento e/ou prevenção de hiv/aids.
BR112018008011A 2015-10-25 2016-10-24 proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv BR112018008011A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Publications (1)

Publication Number Publication Date
BR112018008011A2 true BR112018008011A2 (pt) 2018-10-30

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008011A BR112018008011A2 (pt) 2015-10-25 2016-10-24 proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv

Country Status (31)

Country Link
US (3) US20190054182A1 (pt)
EP (2) EP3819310A1 (pt)
JP (3) JP7169190B2 (pt)
KR (1) KR20180063336A (pt)
CN (4) CN116675776A (pt)
AR (1) AR106466A1 (pt)
AU (2) AU2016347058B2 (pt)
BR (1) BR112018008011A2 (pt)
CA (1) CA3002664A1 (pt)
CL (1) CL2018001065A1 (pt)
CO (1) CO2018005337A2 (pt)
CR (1) CR20180288A (pt)
DO (1) DOP2018000102A (pt)
EA (1) EA201891028A1 (pt)
ES (1) ES2894304T3 (pt)
HK (1) HK1253385A1 (pt)
HR (1) HRP20211528T1 (pt)
HU (1) HUE056608T2 (pt)
IL (2) IL301140A (pt)
MA (1) MA42641A1 (pt)
MX (2) MX2018005048A (pt)
MY (1) MY192278A (pt)
PE (1) PE20181167A1 (pt)
PH (1) PH12018500873A1 (pt)
PL (1) PL3365366T3 (pt)
RS (1) RS62437B1 (pt)
SG (1) SG11201803324VA (pt)
SI (1) SI3365366T1 (pt)
TW (2) TWI750139B (pt)
UY (1) UY36965A (pt)
WO (1) WO2017074878A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EP3110844B1 (en) * 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
CN116675776A (zh) 2015-10-25 2023-09-01 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
EP4011911A1 (en) * 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
CR20180539A (es) 2016-04-13 2019-02-15 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes
MY192090A (en) * 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20240049621A (ko) 2017-02-17 2024-04-16 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
CA3085351A1 (en) * 2017-12-21 2019-07-11 Aaron Diamond Aids Research Center Bispecific hiv-1-neutralizing antibodies
KR20200109333A (ko) 2018-01-12 2020-09-22 젠자임 코포레이션 폴리펩티드의 정량화를 위한 방법
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CN113166254A (zh) * 2018-10-09 2021-07-23 赛诺菲 三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
WO2020106713A1 (en) * 2018-11-21 2020-05-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
JP2022527994A (ja) 2019-04-09 2022-06-07 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
EP4048690A1 (en) 2019-10-25 2022-08-31 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
CN116157416A (zh) * 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法
TW202334204A (zh) * 2021-12-21 2023-09-01 美商莫德斯醫療公司 條件性活化之抗原結合多肽複合物及其使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
WO2012065055A2 (en) 2010-11-12 2012-05-18 The Rockefeller University Fusion proteins for hiv therapy
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP3865507A1 (en) * 2011-05-17 2021-08-18 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
JP2014533249A (ja) * 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
MX2015007575A (es) 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
US20140213772A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
RS59992B1 (sr) * 2013-02-26 2020-04-30 Roche Glycart Ag Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije specifični za cd3 i cea
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
JP6516740B2 (ja) 2013-08-02 2019-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
EP3176185A1 (en) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
CA2996848C (en) 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
TW202130662A (zh) 2015-01-23 2021-08-16 法商賽諾菲公司 特異性結合ｃｄ３及／或ｃｄ１２３之抗—ｃｄ３抗體，抗—ｃｄ１２３抗體及雙特異性抗體
JP6936736B2 (ja) 2015-05-20 2021-09-22 クアンタム−エスアイ インコーポレイテッドＱｕａｎｔｕｍ−Ｓｉ Ｉｎｃｏｒｐｏｒａｔｅｄ 時間分解発光を使用して核酸の配列を決定するための方法
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
CN108779161A (zh) 2015-09-22 2018-11-09 宾夕法尼亚大学董事会 重定向t细胞以治疗hiv感染的方法
CN116675776A (zh) 2015-10-25 2023-09-01 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
TWI814056B (zh) 2015-12-15 2023-09-01 美商基利科學股份有限公司 人類免疫不全病毒中和抗體
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
CR20180539A (es) 2016-04-13 2019-02-15 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes
US20230242876A1 (en) 2016-12-30 2023-08-03 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
KR20240049621A (ko) 2017-02-17 2024-04-16 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
BR112019020235A2 (pt) 2017-03-27 2020-04-22 Inovio Pharmaceuticals Inc molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
CN113166254A (zh) 2018-10-09 2021-07-23 赛诺菲 三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
PH12018500873A1 (en) 2018-11-12
KR20180063336A (ko) 2018-06-11
AU2024200395A1 (en) 2024-04-11
PL3365366T3 (pl) 2022-01-31
US20220226495A1 (en) 2022-07-21
JP2023085476A (ja) 2023-06-20
US11779651B2 (en) 2023-10-10
JP7169190B2 (ja) 2022-11-10
EA201891028A1 (ru) 2019-02-28
CN116789841A (zh) 2023-09-22
MY192278A (en) 2022-08-16
JP2021072847A (ja) 2021-05-13
DOP2018000102A (es) 2018-11-30
HK1253385A1 (zh) 2019-06-14
TWI750139B (zh) 2021-12-21
WO2017074878A8 (en) 2018-05-24
AU2016347058B2 (en) 2023-11-09
TW202219064A (zh) 2022-05-16
AU2016347058A1 (en) 2018-06-14
US20200054765A1 (en) 2020-02-20
IL258822A (en) 2018-06-28
ES2894304T3 (es) 2022-02-14
CN117069855A (zh) 2023-11-17
IL301140A (en) 2023-05-01
CR20180288A (es) 2018-09-11
EP3819310A1 (en) 2021-05-12
WO2017074878A1 (en) 2017-05-04
IL258822B1 (en) 2023-04-01
CN116675776A (zh) 2023-09-01
HRP20211528T1 (hr) 2021-12-24
US11129905B2 (en) 2021-09-28
CA3002664A1 (en) 2017-05-04
CN109311966B (zh) 2023-03-10
MX2018005048A (es) 2018-09-06
JP7328267B2 (ja) 2023-08-16
IL258822B2 (en) 2023-08-01
SI3365366T1 (sl) 2022-02-28
JP2018537966A (ja) 2018-12-27
US20190054182A1 (en) 2019-02-21
CN109311966A (zh) 2019-02-05
PE20181167A1 (es) 2018-07-19
RS62437B1 (sr) 2021-11-30
CO2018005337A2 (es) 2018-07-10
MA42641A1 (fr) 2019-03-29
EP3365366A1 (en) 2018-08-29
HUE056608T2 (hu) 2022-02-28
MX2022014631A (es) 2023-01-11
SG11201803324VA (en) 2018-05-30
AR106466A1 (es) 2018-01-17
TW201730210A (zh) 2017-09-01
CL2018001065A1 (es) 2018-11-23
UY36965A (es) 2017-05-31
EP3365366B1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
BR112018008011A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
BR112018070998A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
EA201890278A1 (ru) Антитела к pd-l1
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2018115017A3 (en) CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR
NZ759601A (en) Aggrecan binding immunoglobulins
TN2018000180A1 (en) Polypeptides inhibiting cd40l
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
BR112021020346A2 (pt) Proteínas de ligação triespecíficas e/ou trivalentes que utilizam o formato de domínios variáveis duplos para cruzamento (codv) para o tratamento de infecção por hiv
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
BR112021019915A2 (pt) Proteínas de ligação triespecíficas, métodos e usos dos mesmos
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]